Výsledky vyhledávání - "Jose Tabernero"

Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN

Publikováno v: Methods (San Diego, Calif.)

Prostate cancer is among the most frequent cancers in men, and despite its high rate of cure, the high number of cases results in an elevated mortality worldwide. Importantly, prostate cancer incidence is dramatically increasing in western societies

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f73916116be53283e7bff58efaf0a2

Zobrazit plný text záznamu

Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial

Autor: Jose Tabernero, Juan José Reina, Jorge Aparicio, Encarnación González-Flores, Alfredo Carrato, Eduardo Díaz-Rubio, M. Chaves, Enrique Aranda, Auxiliadora Gómez-España, Ferran Losa, Bartomeu Massuti, Fernando Rivera, Alberto Abad, Joan Maurel, Javier Sastre, Bernardo Queralt

Publikováno v: Journal of Clinical Oncology. 25:4224-4230

Purpose The aim of this phase III trial was to compare the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose fluorouracil (FU) plus oxaliplatin (FUOX) regimens as first-line therapy for me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f499f95034b381177777b71aacacc8dd
https://doi.org/10.1200/jco.2006.09.8467

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)

Autor: Raúl Cassia, Serena Di Cosimo, Gema Moreno-Bueno, Sonia Rodríguez, Marta Guzman, Federico Rojo, Jose Tabernero, José Baselga, Pablo Matar, Joaquín Arribas, J Palacios

Publikováno v: Clinical Cancer Research. 10:6487-6501

Purpose: The epidermal growth factor receptor (EGFR) is abnormally activated in cancer and two classes of anti-EGFR agents, monoclonal antibodies and low-molecular-weight tyrosine kinase inhibitors, have shown antitumor activity in patients. Because

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ea9db59aa140e4b09dffef1293a5c6c4
https://doi.org/10.1158/1078-0432.ccr-04-0870

Zobrazit plný text záznamu

Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study

Autor: Ferran Losa, Albert Abad, Javier Sastre, M. Chaves, Pedro Sánchez-Rovira, Eduardo Díaz-Rubio, Bartomeu Massuti, Encarnación González-Flores, Enrique Aranda, Alfredo Carrato, Auxiliadora Gómez-España, Bernardo Queralt, Jose Tabernero, T. García, Juan José Reina, Fernando Rivera, I. Maestu

Publikováno v: Critical reviews in oncology/hematology. 70(2)

Purpose Healthy elderly patients with metastatic colorectal cancer may benefit from chemotherapy as much as the younger population. This analysis compares the outcomes of first-line oxaliplatin plus fluoropyrimidines in elderly versus young patients.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d86c6793342dff6850a69b0c656fee3
https://pubmed.ncbi.nlm.nih.gov/19111473

Zobrazit plný text záznamu

First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

Publikováno v: Scopus-Elsevier

Purpose. The aim of this phase III trial was to compare the efficacy and safety of bevacizumab alone with those of bevacizumab and capecitabine plus oxaliplatin (XELOX) as maintenance treatment following induction chemotherapy with XELOX plus bevaciz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6e2fded3a2a02b1165da37732440df1
http://www.scopus.com/inward/record.url?eid=2-s2.0-84865082849&partnerID=MN8TOARS

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání